🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Report on oncogenic #MET fusions Cancer Discovery - in analysis of >46,000 solid tumors, MET rearrangements seen in ~0.04%. Phase II study of the type I MET TKI vebreltinib here showed RR 50% and DCR 79%, with activity seen in NSCLC, cholangiocarcinoma, others. aacrjournals.org/cancerdiscover…

In a new study published in Clinical Cancer Research, Dana-Farber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. Dana-Farber's Lowe Center for Thoracic Oncology Read more: bit.ly/3GhpAhM

🗨️ Can patients with NSCLC experience long-term disease control after discontinuing ICIs due to adverse events? 🫁 A recent study in Clinical Cancer Research by Mark Awad of Memorial Sloan Kettering Cancer Center and Federica Pecci of Dana-Farber provided key insights. ➡️ Learn more: lungcancerstoday.com/post/can-patie…

Adjuvant osimertinib (EGFR) and alectinib (ALK) are new standards in resectable NSCLC. Trials like NeoADAURA, ALNEO/NAUTIKA1 evaluate perioperative (neoadj/adj) TKIs in EGFR, ALK, KRAS G12C, BRAF, RET (LIBRETO 432), NTRK & MET ascopubs.org/doi/pdf/10.120…

Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/43beXGr

🗨️ Can patients with NSCLC experience long-term disease control after discontinuing ICIs due to adverse events? 🫁 Check out our story on a recent study in Clinical Cancer Research by Mark Awad of Memorial Sloan Kettering Cancer Center and Federica Pecci of Dana-Farber. ➡️ Learn more: buff.ly/FyWppXR

🚨 New insights in #RETpositive #LungCancer: RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist 🧬 Dynamic changes post-treatment — fresh biopsy recommended 💡 Supports ADC & bispecific antibody trials

Alessandro Di Federico presenting our collaborative study on 1st line BRAF/MEKi vs. #ICI for mNSCLC at #ASCO2025. ⬆️ OS with #ICI particularly in pts w/ PDL1 >1%, h/ tobacco use & TP53m. ASCO Marcelo Corassa, MD. Marcelo Negrao Dana-Farber MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

Proud of Drs. #ValentinaSanto & #EleonoraGariazzo—talented, humble, & patient-centered—for presenting their work on biomarkers of response/resistance to #ICI in pts w/ #SqNSCLC (42) & w/o history of smoking (43) at #ASCO25. #IMG true force for progress. Rafeh Naqash, MD ASCO

Pleasure to see Marcello Tiseo at #ASCO2025 presenting the ALNEO academic study by the GOIRC group and making the whole 🇮🇹 thoracic oncogy community proud! ASCO ALK+ International

What about the rare stuff? Biagio Ricciuti, MD, PhD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25

Mark Awad and Federica Pecci share new findings that suggest survival benefits may persist even after stopping ICI treatment. 🔗 Learn more in ILCN: bit.ly/45Qw6qm

Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. OncoAlert Dana-Farber Isabella Soares

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… Mark Awad Biagio Ricciuti, MD, PhD

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements brnw.ch/21wTyDv By Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Pasi Janne, Mark Awad, and colleagues Dana-Farber Memorial Sloan Kettering Cancer Center

In a new JAMA Oncology study, Biagio Ricciuti, MD, PhD Dana-Farber found chemoimmunotherapy before surgery may offer a path forward for patients with advanced stage III non-small cell lung cancer. Read more: bit.ly/445t1li

Our VJ Oncology discussion on lung cancer highlights from #ASCO25 with João Alessi, MD is also available on YouTube 👇 IASLC ASCO OncoAlert EGFR Resisters OncoDaily youtube.com/watch?v=MPmobo…